Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense and Sars

The summary for the Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense and Sars grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense and Sars: The National Institute of Allergy and Infectious Diseases (NIAID) invites investigator-directed cooperative research grant applications that will lead to the development of new vaccines, adjuvants, therapeutics, immunotherapeutics or diagnostics. These products should be focused on the toxins or pathogens listed in the NIAID Categories A, B and C list of priority pathogens (http://www.niaid.nih.gov/dmid/bioterrorism/bandc_priority.htm), or their arthropod vectors. Products focused on the newly recognized SARS Coronavirus are also responsive. The objective of this program is to support research in the early stages of product development (i.e., beyond basic research); however, for the area of immunotherapeutics more basic research is also appropriate. Research may include, but is not limited to, target identification, the adaptation of platform technologies or products to biodefense or SARS applications, optimization of products, process development, early validation and testing, preclinical evaluation, scale-up, and production of quantities sufficient for preclinical regulatory requirements and clinical Phase I testing or field trials. Phase I, II, and III clinical trials and field studies are not supported by this initiative. Applications should define the proposed project goal, interim objectives (development milestones) and potential ultimate product, and provide a schedule or timeline for milestone and goal attainment. Applications that include collaborations between researchers from different disciplines and/or with the private sector (e.g. pharmaceutical, chemical or biotechnological companies) are strongly encouraged. The NIAID recognizes that the inherent nature and demands of the product development process may require funding large, complex grants with interdependent specific aims. Furthermore, some aspects of the product development process (e.g., production of GLP and cGMP product) are inherently not innovative. Recognizing that product development is often an iterative and sequential process, and that steps early in the process may not be successful and may need to be modified or reworked, NIAID staff, through the cooperative agreement grant mechanism, will be actively involved in evaluating the milestones of awardees and determining whether additional investment in the development is warranted.